Bibliographic Details
| Title: |
Urokinase, CX3CL1, CCL2, TRAIL and IL‐18 induced by interferon‐β treatment. |
| Authors: |
Zhukovsky, Christina (AUTHOR), Herman, Stephanie (AUTHOR), Wiberg, Anna (AUTHOR), Cunningham, Janet L. (AUTHOR), Kultima, Kim (AUTHOR), Burman, Joachim (AUTHOR) |
| Source: |
Acta Neurologica Scandinavica. Jun2021, Vol. 143 Issue 6, p602-607. 6p. |
| Subjects: |
Urokinase, Blood proteins, Interferon beta-1a, Interferons |
| Abstract: |
Objective: To identify serum proteins associated with MS and affected by interferon beta treatment. Methods: Plasma samples from 29 untreated relapsing‐remitting MS patients and 15 healthy controls were investigated with a multiplexed panel containing 92 proteins related to inflammation. Follow‐up samples were available from 13 patients at 1 and 3 months after initiation of treatment with interferon beta‐1a. Results: Ten proteins were differentially expressed in MS patients. Five of these were altered by treatment with IFN‐β 1a: uPA, CX3CL1, CCL2, TRAIL and IL18. Conclusion: CCL2 and TRAIL were confirmed to be modulated with interferon beta treatment in MS. As novel findings, we now report that uPA and CX3CL1 were differentially expressed in MS and increased after IFN‐beta‐1a treatment. Conflicting results have been reported on how interferon beta affects IL‐18. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Psychology and Behavioral Sciences Collection |
